Andere Sprachen Phathom Pharmaceuticals, Inc.

Aktien

A2PT0F

US71722W1071

PHAT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
9.18 ^USD	+0.88%		+2.34%	+0.55%

07.03.	Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024
07.03.	Phathom Pharmaceuticals, Inc. meldet Ergebnis für das vierte Quartal bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Phathom Pharmaceuticals : Corporate Overview – April 2024	12.04.
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	03.04.
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	03.04.
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, 'VOQUEZNA Can Kick Some Acid'	27.03.
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”	26.03.
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07.03.
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024	29.02.
Phathom Pharmaceuticals Announces VOQUEZNA Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	14.02.
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	13.02.
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	13.02.
Phathom Pharmaceuticals Announces Voquezna® Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	13.02.
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31.01.
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31.01.
Phathom Pharmaceuticals, Inc.(NasdaqGS:PHAT) dropped from S&P Pharmaceuticals Select Industry Index	18.12.
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital	14.12.
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	07.12.
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	06.12.
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	06.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Phathom Pharmaceuticals, Inc.

Aktien

A2PT0F

US71722W1071

PHAT

Andere Sprachen

Filter